Neuroendocrine gut and pancreatic tumors are known to contain and secret different peptide hormones and amines. During the last two decades, many radioimmunoassays and Elizas have been developed to analyze these substances in blood and urine, which has enabled clinicians to improve the diagnosis and monitoring of patients with various neuroendocrine tumors. Due to cost constraints in medical care, it is important to try to define the most useful biochemical markers from the clinical point of view.
INTRODUCTION
Neuroendocrine gut and pancreatic tumors are known to contain and secrete different peptide hormones and amines. During the last two decades, many radioimmunoassays and Elizas have been developed for analyzing peptide hormones and amines in the blood and urine. Such assays have enabled clinicians to improve the diagnosis and monitoring of patients with various neuroendocrine tumors.
There are several well-known clinical syndromes related to specific hormone production in patients with endocrine pancreatic tumors. The most frequent type of endocrine pancreatic tumor, which also can be confined in the duodenum and rarely outside the gut, is the gastrinoma, producing high amounts of gastrin causing the Zollingera To whom all correspondence should be addressed: Kjell Oberg, M For the biochemical work-up in patients with neuroendocrine GEP tumors, all these peptides mentioned above can be analyzed both by histopathology as well as by radioimmunoassays and Elizas for detection in the plasma or serum using antibodies against the different hormones and amines. Today, however, due to increased costs of medical care, it is important to attempt a cost-benefit analysis when trying for the ultimate biochemical diagnosis of these tumors. When the patients suffer small tumors or present intermittent symptoms, provocative tests might supplement basal measurements of peptides and amines. Today it is also of interest to combined the biochemical characterization of neuroendocrine tumors with markers for cell proliferation, cell adhesion, growth factor/receptor expression, content of somatostatin receptor subtypes and also induction of specific enzymes induced by interferon such as P 68 kinase (PKR) and 2-5A synthetase.
This overview will discuss a general tumor marker for neuroendocrine tumor, chromogranin A and also more specifically biochemical diagnosis of patients with midgut carcinoids, the Zollinger-Ellison syndrome and hypoglycemia. Useful stimulatory tests will be presented, and in the end, markers of tumor biology. CHROMOGRANIN A Chromogranins or secretogranins constitute a family of water-soluble glycoproteins, widely distributed in the secretory granules of the neuroendocrine tissues. The physiological role of the molecules is unclear, but a number of possible biological functions have been postulated including regulation of secretory granule function and serving as a precursor molecule for biologically active peptides [3] .
Chromogranins can serve as cytochemical markers for neurendocrine tissues and as a diagnostic tool for neuroendocrine tumors. Because of their water-soluble properties, chromogranins are secreted together with peptide hormones and can be detected in the blood by radioimmunoassay techniques. Accordingly, chromogranins can serve as circulating tumor markers for neuroendocrine tumors of different origin [4, 5] .
Chromogranin A is a 48 kd glycoprotein, which is stored in the large dense core vesicles containing protein and peptide hormones. The gene on chromosome 14 encode for a single amino acid chain with an terminal signal peptide that directs the protein into the trans-Golgi regulated pathway [6] . Chromogranin A contains several di-basic amino acid positions that serve as potential cleavage sites for production of biological active peptides [7] . Identified peptides with established biological functions derived from chromogranin A are pancreastatin (CgA 249-301), P-granin (CgA 1-114), chromostatin and vasostatin CgA 1-77 [7] (Figure 1 ). Other members of the chromogranin or secretogranin family are chromogranin B or secretogranin I and chromogranin C or secretogranin II. These two members share similar properties but are stored in different tissues. Chromogranin A as well as chromogranin B are originally isolated from chromaffin cells in the bovine adrenal medulla, whereas chromogranin C was isolated from the anterior pituitary. Chromogranin A and B are present in the human adrenal medulla in about equal amounts, but chromogranin C is mainly found in the pituitary [8, 9] . The main source of circulating chromogranin A is the adrenal medulla, but other neuroendocrine tissues contribute [10] .
CHROMOGRANINS AS TUMOR MARKER
In a recent study, we developed specific antibodies against chromogranin A, B and C as well as pancreastatin [11] . The 2). Urinary measurements of the same peptides revealed lower numbers of patients with elevated levels in 39 percent, 15 percent, 14 percent and 33 percent, respectively. Gel permetion chromatography of plasma and urine from nine patients showed that the circulating chromogranin A has a higher molecular weight than chromogranin A excreted to the urine [12] .
Chromogranin A is increased in about 90 percent of patients with various neuroendocrine tumors, however, somewhat lower number of patients with increased levels have been found in insulinomas. In those patients, chromogranin B might be a more useful marker. Although pancreastatin is a fragment of chromogranin A, it is a less sensitive [15] . Calcium infusion test with measurement of gastrin can be used in selected cases but with lower sensitivities (40-70 percent) [15, 16] . Pentagastrin stimulation of tachykinin release in patients with carcinoid tumors might be of value for early detection of classical midgut carcinoids. Pentagastrin 0.6 gg/kg is injected with measurements of tachykinin for 20 minutes. A positive test shows a peak within five minutes after injection [17] .
MARKERS OF TUMOR BIOLOGY
Besides a characterization of the hormone production in different neuroendocrine tumors, it is of value to try to evaluate the growth potential of the tumors. This can be done by staining tissue sections for proliferation markers such as Ki67 or PCNA [18] . Other informative markers might be the adhesion molecule CD44 where expression of higher molecular forms of CD44 is related to worse prognoses in many malignancies [19] . Another marker of bad prognosis is the expression of PDGF-a receptor, which has been shown both for ovarian tumor as well as carcinoids [20] . A complete work-up in these patients should also include analyses of subtypes of somatostatin receptors and induction of 2-SA syntethase as well as PKR. The last two being enzymes that are induced by xinterferon and can be used as prognostic markers [21] .
In conclusion, the basis for biochemical diagnoses in neuroendocrine tumors is measurements of chromogranin A, which can be used as a general screening marker but should be supplemented in the various syndromes with the more specific analyses such as urinary 5-HIAA in patients with carcinoid tumors, gastrin in Zollinger-Ellison patients and insulin/pro-insulin in hypoglycemic patients. For monitoring patients during treatment, chromogranin A is a good marker to follow, although the day-to-day variation might be as high as 38 percent. Plasma levels of chromogranin A might be of prognostic value for carcinoid patients. Assessments of parameters for tumor growth potential and tumor biology should be included in the future to be able to improve the therapeutic outcome.
